Targeting PIKfyve-driven lipid metabolism in pancreatic cancerCaleb Cheng, Arul M. Chinnaiyan, Ke Ding et al.|Nature|2025Cited by 37
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Cell Reports Medicine|2024Cited by 28
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Yuanyuan Qiao et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Proceedings of the National Academy of Sciences|2025Cited by 6
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Rahul Mannan et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 4